CA
NZ
UK
AU
IND
US
Daan Guido Maria Van Well, an officer of SOPHiA GENETICS SA, filed a Form 144 notice on November 9, 2026, disclosing a proposed sale of 1,411 shares of common stock on NASDAQ under a Rule 10b5-1 plan.
Robert Dennehy, Senior Vice President and Chief Operating Officer of MACOM Technology Solutions Holdings, Inc., filed a Form 4 on November 9, 2026, disclosing changes in his beneficial ownership of common stock tied to the vesting of performance-based restricted stock units and restricted stock …
Ambra R. Roth, SVP, General Counsel and Secretary of MACOM Technology Solutions Holdings, Inc., filed a Form 4 on November 9, 2026, disclosing a series of share acquisitions, tax-withholding disposals, and open-market sales of common stock between November 5 and November 9, 2026.
Donghyun Thomas Hwang, SVP of Global Sales at MACOM Technology Solutions Holdings, Inc. (NASDAQ:MTSI), filed a Form 4 on November 9, 2026, disclosing PRSU vesting, share acquisition, and tax-related share withholding transactions dated November 5 and November 6, 2026.
John F. Kober III, an officer of MACOM Technology Solutions Holdings, Inc., filed a Form 144 notice on November 9, 2026, disclosing a proposed sale of 973 shares of common stock through Morgan Stanley Smith Barney LLC.
Carvana Co. officer Thomas Taira filed a Form 144 notice on November 9, 2026, disclosing a proposed sale of 5,596 shares of Carvana common stock with an aggregate market value of $411,697.72.
MACOM Technology Solutions Holdings, Inc. officer Ambra Roth filed a Form 144 notice of proposed sale of securities on November 9, 2026, covering 9,497 shares of common stock with an aggregate market value of $2,003,677.06.
Trevor R. Burgess, Chief Executive Officer and Director of Neptune Insurance Holdings Inc., filed a Form 4 on November 9, 2026, disclosing the sale of 171,285 shares of Class A Common Stock across two trading days under a pre-established Rule 10b5-1 plan.
Matthew Duffy, an officer and director of Neptune Insurance Holdings Inc., filed a Form 144 notice on November 9, 2026, disclosing a proposed sale of 88,000 shares of common stock on the NYSE.
Director B Lynne Parshall filed a Form 144 notice with the SEC on November 9, 2026, disclosing a proposed sale of 5,000 shares of Cytokinetics, Incorporated common stock on NASDAQ.
Please wait processing your request...